Dillon Voss

EDUCATION

B.S. California Univ. of PA, Biology with a Minor in Chemistry, 2012

M.S. Case Western Reserve University, Medical Physiology, 2016

SUMMARY

After graduating college, Dillon joined the lab of Eli E. Bar at Case Western Reserve University, where he studied the hypoxic tumor microenvironment of high-grade gliomas, and identified small-molecule compounds that disrupt various signaling nodes of common cancer stem-cell (CSC) maintenance pathways. He also explored the role of hypoxia in regulating alternative splicing in cancer, which he found particularly interesting and ultimately led him to join the Krainer lab. His current work includes investigating the connection between cancer metabolism and alternative splicing in hepatocellular carcinoma, and identifying vulnerabilities that can be targeted with antisense oligonucleotides (ASOs). He enjoys activities such as rock climbing, golfing, cycling, running, and swimming. 

PUBLICATIONS

Ma, W.K., Voss, D.M., Scharner, J., Costa, A.S.H., Lin, K.-T., Jeon, H.Y., Wilkinson, J.E., Jackson, M., Rigo, F., Bennett, C.F., Krainer, A.R. (2022). ASO-Based PKM Splice-Switching Therapy Inhibits Hepatocellular Carcinoma Growth. Cancer Res. 82, 900-915.

Kim, Y.J., Sivetz, N., Layne, J., Voss, D.M., Yang, L., Zhang, Q., and Krainer, A.R. (2022). Exon-skipping antisense oligonucleotides for cystic fibrosis therapy. Proc. Natl. Acad. Sci. USA. 119, e2114858118.

Voss, D.M.*, Sloan, A.*, Spina, R., Ames, H.M., and Bar, E.E. (2020). The Alternative Splicing Factor, MBNL1, Inhibits Glioblastoma Tumor Initiation and Progression by Reducing Hypoxia-Induced Stemness. Cancer Res. 80, 4681-4692.

Spina, R., Voss, D.M., Yang, X., Sohn, J.W., Vinkler, R., Schraner, J., Sloan, A., Welford, S.M., Avril, N., Ames, H.M., Woodworth, G.F., Bar, E.E. (2020). MCT4 regulates de novo pyrimidine biosynthesis in GBM in a lactate-independent manner. Neurooncol Adv. 2, vdz062.

Spina, R., Voss, D.M., Asnaghi, L., Sloan, A., and Bar, E.E. (2018). Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells. J Vis Exp 131: 56176.

Voss, D.M., Spina, R., Carter, D.L., Lim, K.S., Jeffery, C.J., and Bar, E.E. (2017). Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. Sci Rep. 7, 4292.

Spina, R., Voss, D.M., Asnaghi, L., Sloan, A., and Bar, E.E. (2016). Atracurium Besylate and other neuromuscular blocking agents promote astroglial differentiation and deplete glioblastoma stem cells. Oncotarget. 7, 459-472.